Palatin Technologies (PTN) Q1 2025 earnings summary

Executive summary

• Core focus shifted to obesity programs, with multiple clinical trials planned for 2025 targeting general obesity, weight loss management, and rare MC4R pathway diseases.

• Strategic options being explored for non-obesity assets, with significant interest in dry eye, glaucoma, retina, and ulcerative colitis programs.

• Obesity portfolio includes a Phase II combination study and two next-generation MC4R agonist programs advancing toward clinical studies in 2025.

• Patient enrollment for Phase 2 BMT-801 obesity study completed in October 2024; topline results expected 1Q 2025.

• Current pipeline includes Phase 2 and 3 programs in obesity, erectile dysfunction, dry eye disease, ulcerative colitis, and diabetic nephropathy.

Financial highlights

• No product sales or revenue recorded for the quarter ended September 30, 2024, following the sale of Vyleesi rights.

• Prior year’s same quarter gross product sales were $4.6 million, net product revenue $2.1 million.

• Net loss increased to $7.8 million ($0.39/share) from $5.2 million ($0.43/share) year-over-year, primarily due to loss of Vyleesi revenue.

• Operating expenses decreased to $7.8 million from $8.2 million year-over-year, mainly due to reduced selling expenses.

• Cash and cash equivalents were $2.4 million as of September 30, 2024, down from $9.5 million at June 30, 2024.

Outlook and guidance

• Topline results for Phase II obesity combination study and Phase II ulcerative colitis study expected in Q1 2025.

• Topline data for the Phase II diabetic kidney disease study anticipated in Q4 2024.

• IND-enabling activities and clinical studies for two MC4R obesity programs planned for 2025.

• Management expects existing cash to fund operations into the first half of 2025; additional funding will be required.

• Ongoing funding and collaboration discussions for ocular and other non-obesity programs.